Court’s decision
The Delhi High Court granted an interim injunction in favour of GlaxoSmithKline Pharmaceuticals Ltd., restraining Zee Laboratories Limited from using the marks “FEXIT”, “FEXIT-B” and “FEXIT-M” for pharmaceutical products.
Justice Tejas Karia held that the impugned marks are phonetically and structurally deceptively similar to the registered mark “PHEXIN”, particularly in the pharmaceutical sector where a stricter standard applies. The Court found a strong prima facie case of infringement and passing off, observing that even initial interest confusion in medicinal products poses serious public health risks .
Facts
GlaxoSmithKline Pharmaceuticals Ltd., a member of the global GlaxoSmithKline group with presence in India since 1924, is the registered proprietor of the trademark “PHEXIN” in Class 05 since 7 March 1984. The mark has been used since 1985 for extended-release antibiotic capsules used in treatment of respiratory tract, urinary tract, and bacterial infections.
The Plaintiff’s packaging, as seen on page 3 of the judgment, reflects a distinctive white and green trade dress with clear branding of “Phexin” on Cephalexin capsules. The advertising expenditure chart reproduced on page 3 demonstrates consistent promotional spending over several years, evidencing commercial goodwill.
The Defendant was using the marks “FEXIN”, “FEXIN-F”, “FEXIT”, “FEXIT-B” and “FEXIT-M” for pharmaceutical ointments. During proceedings, the Defendant agreed to discontinue “FEXIN” but contested injunction against “FEXIT” variants.
Issues
The Court examined:
- Whether “FEXIT”, “FEXIT-B” and “FEXIT-M” are deceptively similar to “PHEXIN”.
- Whether likelihood of confusion exists despite difference in dosage form (capsule vs ointment).
- Whether the prefix “FEXI” is common to trade, diluting exclusivity.
- Whether delay or coexistence disentitled the Plaintiff from interim relief.
Plaintiff’s arguments
The Plaintiff contended that “PHEXIN” is a registered and widely used antibiotic brand with decades of goodwill. It argued that “FEXIT” is phonetically similar and likely to be confused, particularly given India’s multilingual environment and the risk of slurring in pronunciation.
It emphasized that in pharmaceutical trademark disputes, courts must adopt a stricter approach due to public health implications. Reliance was placed on established precedent that pharmacists and doctors are not immune to error, and illegible prescriptions heighten risk.
The Plaintiff further argued that the Defendant had copied its green-and-white trade dress, strengthening likelihood of confusion and injurious association.
Defendant’s arguments
The Defendant argued that the products were distinct in nature and administration—oral antibiotic capsules versus topical dermatological ointments. Both were Schedule H prescription drugs, reducing likelihood of confusion.
It asserted long-standing use of “FEXIT” since 2007, supported by manufacturing licences and invoices. It also argued that “FEXI” is common to trade, pointing to multiple registered marks containing the prefix.
Relying on precedents, the Defendant submitted that absence of actual confusion and prolonged coexistence should weigh against injunction.
Analysis of the law
The Court applied the settled principles governing pharmaceutical trademark infringement under Section 29 of the Trade Marks Act, 1999. It reiterated that mere likelihood of confusion suffices; proof of actual confusion is unnecessary.
The Court emphasized the stricter standard mandated in medicinal product cases. Even minor phonetic similarity may have life-threatening consequences. The doctrine of initial interest confusion was invoked, recognizing that diversion of consumer attention at the preliminary stage constitutes infringement.
Precedent analysis
The Court relied on Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd., where the Supreme Court mandated heightened vigilance in medicinal product cases.
It also referred to Glenmark Pharmaceuticals Ltd. v. Sun Pharma Laboratories Ltd. and Sun Pharmaceuticals Laboratories Ltd. v. Hetero Healthcare Ltd., reaffirming that stricter scrutiny applies in pharmaceutical disputes.
On delay, the Court relied on Midas Hygiene Industries Pvt. Ltd. v. Sudhir Bhatia, reiterating that delay is not a defence in cases of dishonest adoption.
The distinction between “common to register” and “common to trade” was reaffirmed, rejecting the Defendant’s reliance on registry search results.
Court’s reasoning
The Court found that “PHEXIN” and “FEXIT” are phonetically similar, especially when pronounced quickly or in multilingual settings. The similarity of prefix and overall structure increased risk of confusion.
It rejected the argument that different dosage forms eliminate confusion, observing that pharmacists and patients may not always exercise perfect recollection. The fact that both products were Schedule H drugs did not negate confusion risk.
The Defendant failed to prove substantial market use of third-party “FEXI” marks. The Court held that mere registry entries do not dilute distinctiveness.
The Court concluded that this was a case of “triple identity”—similar marks, identical product category (pharmaceuticals), and identical consumer base.
Conclusion
The Delhi High Court restrained the Defendant, its directors, distributors and associates from manufacturing, marketing or advertising pharmaceutical products under the marks “FEXIT”, “FEXIT-B” and “FEXIT-M” or any deceptively similar trade dress.
The interim application was disposed of in favour of the Plaintiff .
Implications
This ruling reinforces strict judicial scrutiny in pharmaceutical trademark disputes. It confirms:
• Phonetic similarity alone may justify injunction.
• Mode of administration differences are not decisive.
• Public health concerns override technical distinctions.
• “Common to register” is not equivalent to “common to trade.”
• Delay does not defeat injunction where adoption appears dishonest.
The judgment strengthens brand protection for established pharmaceutical marks and underscores courts’ proactive stance in safeguarding public health.
Case law references
- Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd. (2001) – Stricter test for deceptive similarity in pharmaceutical products.
- Midas Hygiene Industries Pvt. Ltd. v. Sudhir Bhatia (2004) – Delay is not a defence where adoption is dishonest.
- Glenmark Pharmaceuticals Ltd. v. Sun Pharma Laboratories Ltd. – Reinforced strict scrutiny in medicinal trademark disputes.
- Dr. Reddy’s Laboratories Ltd. v. Reddy Pharmaceuticals Ltd. – Third-party use does not dilute plaintiff’s rights absent proof of substantial trade presence.
FAQs
1. Why are pharmaceutical trademark disputes treated more strictly?
Because confusion between medicines can have life-threatening consequences. Courts apply a higher standard of scrutiny to prevent public health risks.
2. Does difference in dosage form prevent trademark infringement?
No. The Delhi High Court clarified that capsules and ointments may still cause confusion if marks are phonetically similar.
3. Is delay in filing a trademark suit fatal?
No. Where adoption appears dishonest or confusingly similar, delay alone does not bar injunction.